Medindia

X

Rigel to Present at the Needham Biotechnology and Medical Technology Conference

Friday, June 6, 2008 General News J E 4
Advertisement
SOUTH SAN FRANCISCO, Calif., June 5 RigelPharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower,Rigel's chairman and chief executive officer, will be presenting a companyoverview at the Seventh Annual Needham Biotechnology and Medical TechnologyConference on Thursday, June 12, 2008 at 2:00 p.m. EDT at The New York PalaceHotel in New York City.

To access the live audio webcast or the subsequent archived recording, logon to http://www.rigel.com. Please connect to Rigel's website several minutesprior to the start of the live webcast to ensure adequate time for anysoftware download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our goal is to file one new investigational new drug (IND)application in a significant indication each year. Rigel has achieved thisgoal every year since 2002. Our pioneering research focuses on intracellularsignaling pathways and related targets that are critical to diseasemechanisms. Rigel's productivity has resulted in strategic collaborations withlarge pharmaceutical partners to develop and market our product candidates.Rigel has product development programs in inflammatory/autoimmune diseasessuch as rheumatoid arthritis, thrombocytopenia and asthma, as well as incancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Phase 1/2 Trial of Motexafin Gadolinium Plus Antib...
S
Fidelity National Financial, Inc. Announces the Sa...